Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors

Recurrent Childhood Rhabdomyosarcoma Clinical Trial

Official title:

A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00070109
• Other study ID #: ADVL0221
• Secondary ID: NCI-2009-00357CD
• Status: Completed
• Phase: Phase 2
• Start date: January 2008
• Est. completion date: December 2013

Study information

• Verified date: August 2018
• Source: Children's Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die.

Description:

PRIMARY OBJECTIVES:

I. Determine the response rate in pediatric patients with recurrent or refractory soft tissue sarcomas or Ewing's sarcoma family of tumors treated with ecteinascidin 743 (trabectedin).

II. Determine the toxicity of this drug in these patients. III. Determine the pharmacokinetics of this drug in these patients.

OUTLINE:

Patients receive trabectedin IV over 3 hours on day 1. Treatment repeats every 21days for up to 26 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for up to 5 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 2013
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Months to 50 Years

Eligibility

Inclusion Criteria:

• Patients must be greater than or equal to 12 months of age at the time of study entry and no more than 21 years of age when initially diagnosed with the malignancy to be treated on this protocol

• Histologically confirmed recurrent or refractory sarcoma tumors, including the following:

• Rhabdomyosarcoma

• Nonrhabdomyosarcomatous soft tissue sarcoma

• Ewing's sarcoma

• Measurable disease by imaging studies

• Lesions assessable only by radionuclide scans are not considered measurable

• If the only measurable lesion has been previously irradiated, then that lesion must have shown evidence of an interim increase in size

• No significant amount of metastatic liver disease, defined as the following:

• Lesions occupying more than 25% of the liver by imaging and abnormal liver function tests or abnormal synthetic liver function

• Performance status - Lansky 50-100% (10 years of age and under)

• Performance status - Karnofsky 50-100% (over 10 years of age)

• Absolute neutrophil count at least 1,000/mm^3

• Platelet count at least 100,000/mm^3 (transfusion independent)

• Hemoglobin at least 8.0 g/dL (transfusion allowed)

• No concurrent CYP3A4 inhibitors, including the following:

• Grapefruit juice

• Erythromycin

• Azithromycin

• Clarithromycin

• Rifampin and its analogs

• Fluconazole

• Ketoconazole

• Itraconazole

• Cimetidine

• Cannabinoids (marijuana or dronabinol)

• Leukotriene inhibitors used in asthma (e.g., zafirlukast, montelukast, or zileuton)

• Bilirubin no greater than upper limit of normal (ULN)

• Total alkaline phosphatase no greater than ULN

• Hepatic fraction alkaline phosphatase and 5 nucleotidase no greater than ULN

• SGOT and SGPT = 2.5 times ULN

• Albumin = 2.5 g/dL

• Gamma-glutamyl transferase < 2.5 times ULN

• Maximum creatinine based on age as follows:

• 0.8 mg/dL (5 years of age and under)

• 1.0 mg/dL (6 to 10 years of age)

• 1.2 mg/dL (11 to 15 years of age)

• 1.5 mg/dL (over 15 years of age)

• Creatinine clearance or radioisotope glomerular filtration rate (GFR) at least 70 mL/min

• No uncompensated congestive heart failure within the past 6 months

• Not pregnant or nursing

• Fertile patients must use effective contraception during and for 2 months after study participation

• No active uncontrolled infection

• Weight = 15 kilograms

• More than 1 week since prior growth factors that support platelet or white blood cell number or function

• At least 7 days since prior biologic agents and recovered

• No prior allogeneic stem cell transplantation

• No other concurrent immunomodulating agents

• More than 3 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered

• No more than 2 prior multi-agent chemotherapy regimens

• No other concurrent anticancer chemotherapy

• Concurrent steroids allowed

• At least 6 weeks since prior since prior extended radiotherapy and recovered

• No prior total body radiotherapy

• Concurrent radiotherapy to localized painful lesions allowed provided at least 1 measurable lesion is not irradiated*

• At least 7 days since prior enzyme-inducing anticonvulsants (e.g., carbamazepine, phenobarbital, or phenytoin)

• No concurrent enzyme-inducing anticonvulsants

• No other concurrent investigational agents

Related Conditions & MeSH terms

• Neuroectodermal Tumors
• Neuroectodermal Tumors, Primitive
• Neuroectodermal Tumors, Primitive, Peripheral
• Peripheral Primitive Neuroectodermal Tumor
• Previously Treated Childhood Rhabdomyosarcoma
• Recurrent Childhood Rhabdomyosarcoma
• Recurrent Childhood Soft Tissue Sarcoma
• Recurrent Ewing Sarcoma
• Rhabdomyosarcoma
• Sarcoma
• Sarcoma, Ewing

Intervention

Drug:
• trabectedin
Given IV

Other:
• pharmacological study
Correlative studies

Locations

Country	Name	City	State
Canada	Chedoke-McMaster Hospitals	Hamilton	Ontario
Canada	Hospital Sainte-Justine	Montreal	Quebec
Canada	Hospital for Sick Children	Toronto	Ontario
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	University of Vermont	Burlington	Vermont
United States	Childrens Memorial Hospital	Chicago	Illinois
United States	Nationwide Children's Hospital	Columbus	Ohio
United States	University of Arkansas for Medical Sciences	Little Rock	Arkansas
United States	Children's Hospital Central California	Madera	California
United States	St. Jude Children's Research Hospital	Memphis	Tennessee
United States	Columbia University Medical Center	New York	New York
United States	New York University Langone Medical Center	New York	New York
United States	Seattle Children's Hospital	Seattle	Washington
United States	Wake Forest University Health Sciences	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Children's Oncology Group	National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

References & Publications (1)

Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC, Blaney SM. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Chil — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response (Complete Response [CR] and Partial Response [PR])	Any patient who is enrolled and receives at least one dose of trabectedin will be considered evaluable for response if the individual receives at least one dose of trabectedin and: (1) is removed from protocol therapy because of progressive disease where progressive disease is documented either by imaging studies or clinical progression; or (2) has at least one radiographic evaluation of disease status after the start of protocol therapy and is not electively removed from protocol therapy with stable disease or is not lost to follow-up with stable disease. Patients who achieve a complete response (CR) - disappearance of all target lesions or partial response (PR) - >=30% decrease in the sum of the longest diameter of target lesions according to the RECIST criteria will be considered responders for the study design. All other patients who are evaluable for response will be considered non-responders for the study.	Twenty-six (26) cycles of chemotherapy or termination of protocol therapy, whichever occurs first.
Primary	Number of Patients With Dose-Limiting Toxicity (DLT)	Any Grade 3 or Grade 4 non-hematologic toxicity attributable to the Investigational drug with the specific exclusion of: Grade 3 nausea and vomiting; Grade 3 transaminase (AST/ALT) elevation that return to less than or equal to Grade 1 or baseline prior to the time for the next treatment cycle; Grade 3 fever or infection; Alopecia; Grade 4 neutropenia of > 7 days duration or Grade 4 thrombocytopenia of > 7 days duration, which requires transfusion therapy on greater than 2 occasions in 7 days, or which causes a delay of more than 14 days beyond the planned interval between treatment cycles.	1 Cycle
Primary	Pharmacokinetics by a Miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method : Maximum Plasma Concentration (Cmax) of Trabectedin	The plasma concentrations at each time point were determined by miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method. The plasma concentration-versus-time data of trabectedin were estimated using non-compartmental methods. Individual time points were not available, so one estimated Cmax was derived for each patient.	From baseline up to168 hours after trabectedin infusion in course 1
Primary	Pharmacokinetics by a Miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method : Apparent Volume at Steady State (Vss) of Trabectedin	The plasma concentrations at each time point were determined by miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method. The plasma concentration-versus-time data of trabectedin were estimated using non-compartmental methods. Individual time points were not available, so one estimated Vss was derived for each patient.	From baseline up to168 hours after trabectedin infusion in course 1
Primary	Pharmacokinetics by a Miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method : Half-life of Trabectedin	The plasma concentrations at each time point were determined by miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method. The plasma concentration-versus-time data of trabectedin were estimated using non-compartmental methods. Individual time points were not available, so one estimated Half-life was derived for each patient.	From baseline up to168 hours after trabectedin infusion in course 1
Primary	Pharmacokinetics by a Miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method : Area Under the Curve (AUC) of Trabectedin	The plasma concentrations at each time point were determined by miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method. The plasma concentration-versus-time data of trabectedin were estimated using non-compartmental methods. Individual time points were not available, so one estimated AUC was derived for each patient.	From baseline up to168 hours after trabectedin infusion in course 1
Primary	Pharmacokinetics by a Miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method : Clearance of Trabectedin	The plasma concentrations at each time point were determined by miniaturized Liquid Chromatography/Tandem Mass Spectrometry Method. The plasma concentration-versus-time data of trabectedin were estimated using non-compartmental methods. Individual time points were not available, so one estimated Clearance was derived for each patient.	From baseline up to168 hours after trabectedin infusion in course 1